肝囊肿感染的临床管理:基于改良德尔菲法的国际临床决策框架。

IF 5.5 2区 化学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Biomacromolecules Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI:10.1016/S2468-1253(24)00094-3
Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain, Nicolien M Hanemaaijer, Patrick S Kamath, Pavel Strnad, Richard Taubert, Ron T Gansevoort, Roser Torra, Silvio Nadalin, Tatsuya Suwabe, Tom J G Gevers, Vincenzo Cardinale, Joost P H Drenth, Marten A Lantinga
{"title":"肝囊肿感染的临床管理:基于改良德尔菲法的国际临床决策框架。","authors":"Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain, Nicolien M Hanemaaijer, Patrick S Kamath, Pavel Strnad, Richard Taubert, Ron T Gansevoort, Roser Torra, Silvio Nadalin, Tatsuya Suwabe, Tom J G Gevers, Vincenzo Cardinale, Joost P H Drenth, Marten A Lantinga","doi":"10.1016/S2468-1253(24)00094-3","DOIUrl":null,"url":null,"abstract":"<p><p>Liver cyst infections often necessitate long-term hospital admission and are associated with considerable morbidity and mortality. We conducted a modified Delphi study to reach expert consensus for a clinical decision framework. The expert panel consisted of 24 medical specialists, including 12 hepatologists, from nine countries across Europe, North America, and Asia. The Delphi had three rounds. The first round (response rate 21/24 [88%]) was an online survey with questions constructed from literature review and expert opinion, in which experts were asked about their management preferences and rated possible management strategies for seven clinical scenarios. Experts also rated 14 clinical decision-making items for relevancy and defined treatment outcomes. During the second round (response rate 13/24 [54%]), items that did not reach consensus and newly suggested themes were discussed in an online panel meeting. In the third round (response rate 16/24 [67%]), experts voted on definitions and management strategies using an online survey based on previous answers. Consensus was predefined as a vote threshold of at least 75%. We identified five subclassifications of liver cyst infection according to cyst phenotypes and patient immune status and consensus on episode definitions (new, persistent, and recurrent) and criteria for treatment success or failure was reached. The experts agreed that fever and elevated C-reactive protein are pivotal decision-making items for initiating and evaluating the management of liver cyst infections. Consensus was reached on 26 management statements for patients with liver cyst infections across multiple clinical scenarios, including two treatment algorithms, which were merged into one after comments. We provide a clinical decision framework for physicians managing patients with liver cyst infections. This framework will facilitate uniformity in the management of liver cyst infections and can constitute the basis for the development of future guidelines.</p>","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework.\",\"authors\":\"Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain, Nicolien M Hanemaaijer, Patrick S Kamath, Pavel Strnad, Richard Taubert, Ron T Gansevoort, Roser Torra, Silvio Nadalin, Tatsuya Suwabe, Tom J G Gevers, Vincenzo Cardinale, Joost P H Drenth, Marten A Lantinga\",\"doi\":\"10.1016/S2468-1253(24)00094-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Liver cyst infections often necessitate long-term hospital admission and are associated with considerable morbidity and mortality. We conducted a modified Delphi study to reach expert consensus for a clinical decision framework. The expert panel consisted of 24 medical specialists, including 12 hepatologists, from nine countries across Europe, North America, and Asia. The Delphi had three rounds. The first round (response rate 21/24 [88%]) was an online survey with questions constructed from literature review and expert opinion, in which experts were asked about their management preferences and rated possible management strategies for seven clinical scenarios. Experts also rated 14 clinical decision-making items for relevancy and defined treatment outcomes. During the second round (response rate 13/24 [54%]), items that did not reach consensus and newly suggested themes were discussed in an online panel meeting. In the third round (response rate 16/24 [67%]), experts voted on definitions and management strategies using an online survey based on previous answers. Consensus was predefined as a vote threshold of at least 75%. We identified five subclassifications of liver cyst infection according to cyst phenotypes and patient immune status and consensus on episode definitions (new, persistent, and recurrent) and criteria for treatment success or failure was reached. The experts agreed that fever and elevated C-reactive protein are pivotal decision-making items for initiating and evaluating the management of liver cyst infections. Consensus was reached on 26 management statements for patients with liver cyst infections across multiple clinical scenarios, including two treatment algorithms, which were merged into one after comments. We provide a clinical decision framework for physicians managing patients with liver cyst infections. This framework will facilitate uniformity in the management of liver cyst infections and can constitute the basis for the development of future guidelines.</p>\",\"PeriodicalId\":30,\"journal\":{\"name\":\"Biomacromolecules\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomacromolecules\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/S2468-1253(24)00094-3\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2468-1253(24)00094-3","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

肝囊肿感染通常需要长期入院治疗,发病率和死亡率都相当高。我们开展了一项改良德尔菲研究,以就临床决策框架达成专家共识。专家小组由来自欧洲、北美和亚洲九个国家的 24 位医学专家组成,其中包括 12 位肝病专家。德尔菲共有三轮。第一轮(回复率为 21/24 [88%])是一项在线调查,根据文献综述和专家意见提出问题,询问专家们的管理偏好,并对七种临床情况下可能的管理策略进行评分。专家们还对 14 个临床决策项目进行了相关性评分,并确定了治疗结果。在第二轮(回复率为 13/24 [54%])中,未达成共识的项目和新提出的主题在在线小组会议上进行了讨论。在第三轮(回复率为 16/24 [67%])中,专家们根据之前的答案通过在线调查对定义和管理策略进行投票。共识被预先设定为至少 75% 的投票阈值。我们根据囊肿表型和患者免疫状态确定了肝囊肿感染的五个亚分类,并就发病定义(新发、持续和复发)和治疗成功或失败的标准达成了共识。专家们一致认为,发热和 C 反应蛋白升高是启动和评估肝囊肿感染治疗的关键决策项目。针对多种临床情况下的肝囊肿感染患者,专家们就 26 项管理声明达成了共识,其中包括两种治疗算法,并在征求意见后将其合并为一种算法。我们为管理肝囊肿感染患者的医生提供了一个临床决策框架。该框架将有助于肝囊肿感染的统一管理,并可作为未来制定指南的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework.

Liver cyst infections often necessitate long-term hospital admission and are associated with considerable morbidity and mortality. We conducted a modified Delphi study to reach expert consensus for a clinical decision framework. The expert panel consisted of 24 medical specialists, including 12 hepatologists, from nine countries across Europe, North America, and Asia. The Delphi had three rounds. The first round (response rate 21/24 [88%]) was an online survey with questions constructed from literature review and expert opinion, in which experts were asked about their management preferences and rated possible management strategies for seven clinical scenarios. Experts also rated 14 clinical decision-making items for relevancy and defined treatment outcomes. During the second round (response rate 13/24 [54%]), items that did not reach consensus and newly suggested themes were discussed in an online panel meeting. In the third round (response rate 16/24 [67%]), experts voted on definitions and management strategies using an online survey based on previous answers. Consensus was predefined as a vote threshold of at least 75%. We identified five subclassifications of liver cyst infection according to cyst phenotypes and patient immune status and consensus on episode definitions (new, persistent, and recurrent) and criteria for treatment success or failure was reached. The experts agreed that fever and elevated C-reactive protein are pivotal decision-making items for initiating and evaluating the management of liver cyst infections. Consensus was reached on 26 management statements for patients with liver cyst infections across multiple clinical scenarios, including two treatment algorithms, which were merged into one after comments. We provide a clinical decision framework for physicians managing patients with liver cyst infections. This framework will facilitate uniformity in the management of liver cyst infections and can constitute the basis for the development of future guidelines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomacromolecules
Biomacromolecules 化学-高分子科学
CiteScore
10.60
自引率
4.80%
发文量
417
审稿时长
1.6 months
期刊介绍: Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine. Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信